176 related articles for article (PubMed ID: 34965569)
41. Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.
Moilanen T; Jokimäki A; Tenhunen O; Koivunen JP
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1613-1621. PubMed ID: 29872916
[TBL] [Abstract][Full Text] [Related]
42. Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy.
Yood MU; Wells KE; Alford SH; Dakki H; Beiderbeck AB; Hurria A; Gross CP; Oliveria SA
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):818-27. PubMed ID: 22419528
[TBL] [Abstract][Full Text] [Related]
43. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
[TBL] [Abstract][Full Text] [Related]
44. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
Caron J; Nohria A
Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677
[TBL] [Abstract][Full Text] [Related]
45. Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments.
Ahmed SH; Moussa Sherif DE; Fouad Y; Kelany M; Abdel-Rahman O
Expert Opin Drug Saf; 2016 Jul; 15(7):911-23. PubMed ID: 27007468
[TBL] [Abstract][Full Text] [Related]
46. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
[TBL] [Abstract][Full Text] [Related]
47. [Clinical observation on the anthracyclines-induced cardiotoxicity in patients with early-stage breast cancer].
Hu GF; Fu HX; Ma JF; Hu MF; Zhao ZN; Hu C; Yang J
Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Dec; 46(12):987-992. PubMed ID: 30572405
[No Abstract] [Full Text] [Related]
48. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
[TBL] [Abstract][Full Text] [Related]
49. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
[TBL] [Abstract][Full Text] [Related]
50. The Role of Biomarkers to Evaluate Cardiotoxicity.
Upshaw JN
Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
[TBL] [Abstract][Full Text] [Related]
51. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
Menna P; Minotti G; Salvatorelli E
Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
[TBL] [Abstract][Full Text] [Related]
52. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
53. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
Abouegylah M; Braunstein LZ; Alm El-Din MA; Niemierko A; Salama L; Elebrashi M; Edgington SK; Remillard K; Napolitano B; Naoum GE; Sayegh HE; Gillespie T; Farouk M; Ismail AA; Taghian AG
Breast Cancer Res Treat; 2019 Feb; 174(1):179-185. PubMed ID: 30478787
[TBL] [Abstract][Full Text] [Related]
55. Cardiovascular toxicity of breast cancer treatment: an update.
Papageorgiou C; Andrikopoulou A; Dimopoulos MA; Zagouri F
Cancer Chemother Pharmacol; 2021 Jul; 88(1):15-24. PubMed ID: 33864486
[TBL] [Abstract][Full Text] [Related]
56. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
57. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
[TBL] [Abstract][Full Text] [Related]
58. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
59. Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
Yu AF; Ho AY; Braunstein LZ; Thor ME; Lee Chuy K; Eaton A; Mara E; Cahlon O; Dang CT; Oeffinger KC; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2019 Apr; 32(4):521-528. PubMed ID: 30826225
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of surveillance by echocardiography for cancer therapeutics-related cardiac dysfunction of patients with breast cancer.
Okushi Y; Saijo Y; Yamada H; Toba H; Zheng R; Seno H; Takahashi T; Ise T; Yamaguchi K; Yagi S; Soeki T; Wakatsuki T; Sata M; Kusunose K
J Cardiol; 2023 Dec; 82(6):467-472. PubMed ID: 37481235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
